NATURES SUNSHINE PRODUCTS INC (NATR) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings. Insiders were net buyers over the last 90 days ($2.8M bought vs $0 sold). Latest close $10.32 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.
First Eagle Investment Management — 1 tracked fund hold NATR. See all holders.
Insiders bought on the open market (20 purchases, $2.8M) vs 0 sales ($0). Latest buy: Nov 5, 2026. Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| First Eagle Investment Management | <0.01% | 98,800 | HELD Q3 filed Nov 10 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -52.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 152 of 8,857 filers |
| Long-only filers among them | 152 |
| Change vs 2026 Q1 | +4 net · 147 entered · 143 exited |
| Shares reported, all filers | 15,740,390 |
| Reported value, all filers | $326.7M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $480.1M |
| Net income · FY2025 | $19.5M |
| Total assets · FY2025 | $261.1M |
| Shares outstanding | 17,595,520 |
| Market cap (at latest close) | $181.6M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 24, 2026.
| Shares short · Oct 15, 2026 | 918,670 |
| Share of shares outstanding | 5.22% |
| Days to cover | 8.22 |
Shares short at recent settlements — Jul 31, 2026: 505K · Aug 14, 2026: 545K · Aug 31, 2026: 805K · Sep 15, 2026: 828K · Sep 30, 2026: 857K · Oct 15, 2026: 919K.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 24, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 24, 2026.
1 insider bought on the open market in the last 90 days (20 purchases, $2.8M), against 0 sales by 0 insiders ($0). Latest buy: Nov 5, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. · 781 shares on Nov 5, 2026 · filed Nov 9, 2026 | $9.50 | -5.5% (close Nov 10, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 10, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 781 | $9.50 | $7.4K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 128 | $9.52 | $1.2K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 59,872 | $9.55 | $571.8K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 10,000 | $9.56 | $95.6K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 9,485 | $9.61 | $91.2K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 7,980 | $9.63 | $76.8K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 6 | $9.66 | $58 | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 30 | $9.71 | $291 | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 400 | $9.75 | $3.9K | SEC filing | |
| Nov 5, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | Buy | 774 | $9.77 | $7.6K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Jul 8, 2025 | MOSS RICHARD D | Director | 1,000 | $15.9K | Jul 8, 2025 | SEC filing |
| Jul 7, 2025 | MOSS RICHARD D | Director | 3,500 | $55.0K | Jul 7, 2025 | SEC filing |
| Jul 3, 2025 | MOSS RICHARD D | Director | 1,500 | $23.0K | Jul 3, 2025 | SEC filing |
| Jul 1, 2025 | MOSS RICHARD D | Director | 1,500 | $22.1K | Jul 1, 2025 | SEC filing |
| Jun 25, 2025 | MOSS RICHARD D | Director | 2,000 | $29.8K | Jun 25, 2025 | SEC filing |
| Jun 23, 2025 | MOSS RICHARD D | Director | 3,000 | $44.2K | Jun 23, 2025 | SEC filing |
| Jun 20, 2025 | MOSS RICHARD D | Director | 1,500 | $21.9K | Jun 20, 2025 | SEC filing |
| Jun 18, 2025 | MOSS RICHARD D | Director | 1,000 | $14.5K | Jun 18, 2025 | SEC filing |
| Jun 13, 2025 | MOSS RICHARD D | Director | 734 | $10.6K | Jun 13, 2025 | SEC filing |
| Jun 3, 2025 | MOSS RICHARD D | Director | 1,000 | $14.5K | Jun 3, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jun 27, 2025 | SCHEDULE 13D/A | -30.2% (close Jun 30, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jun 30, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | SC 13G/A | 1,924,486 | 10.9% | Aug 6, 2026 | SEC filing |
| Oct 17, 2025 | BlackRock, Inc. | SC 13G | 889,765 | 5.0% | Sep 30, 2025 | SEC filing |
| Oct 9, 2025 | Dimensional Fund Advisors LP | SC 13G | 913,791 | 5.2% | Sep 30, 2025 | SEC filing |
| Jun 27, 2025 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | SC 13D/A | 64,167 | 0.3% | Jun 25, 2025 | SEC filing |
| Jun 9, 2025 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | SC 13D/A | 2,918,774 | 15.9% | Jun 5, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Insiders
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Deep Value (Templeton) — Stocks that are cheap against both earnings and assets
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Key figures
· Cash Flow (FCF) — Latest FCF: $28.8M · FCF yield: 12.7% · Positive FCF years: 3
· Deep Value (Templeton) — P/E: 11.58 · P/B: 1.40 · Latest EPS: 1.06 · Dividend yield: 0.0%
· Gross Profitability (Novy-Marx) — Gross profit / assets: 133.1% · Gross margin: 72.4%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 2.61 · Operating cash flow: $35.3M · Net income: $19.5M
· Shareholder Yield — Shareholder yield: 7.2% · of which dividends: 0.0% · of which buybacks: 7.2%
· Insider Net Buying — Buy txns: 20 · Sell txns: 0 · Buy value: $2.8M · Latest buy: Nov 5, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold NATR — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 6, 2026 | 2.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
| May 11, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on NATR
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.